Generic drug
Estrogens, esterified (USP) / methyltestosterone price, strengths & recalls
Estrogens, esterified (USP) / methyltestosterone has no weekly pharmacy acquisition cost. 2 manufacturers make it. Its official label last changed on April 24, 2026.
GenericEstrogens, esterified (USP) / methyltestosterone price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 0.625 mg / 1.25 mg tablet | Not priced this week | |||
| 1.25 mg / 2.5 mg tablet | Not priced this week | |||
Supply status: shortages & recalls
What people paid for Estrogens, esterified (USP) / methyltestosterone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
Esterified Estrogens and Methyltestosterone TabletsRx Only
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant Neoplasms, Endometrial Cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular Disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- None on the market
Estrogens, esterified (USP) / methyltestosterone questions
Is estrogens, esterified (usp) / methyltestosterone in shortage?
No shortage is reported for estrogens, esterified (usp) / methyltestosterone right now. We check the national shortage list every day.
Has estrogens, esterified (usp) / methyltestosterone been recalled?
No recalls are on record for estrogens, esterified (usp) / methyltestosterone.
When did the estrogens, esterified (usp) / methyltestosterone label last change?
The official label was last updated on April 24, 2026 (version 103). See what changed.
Talk about estrogens, esterified (usp) / methyltestosterone
No comments yet. Questions, tips, what worked for you - start the conversation.